Rubius Therapeutics’ $100 Million Round Financing

Goodwin advised Rubius in the deal

Rubius Therapeutics completed of an oversubscribed $100 million crossover financing. In just under nine months, the Company has now raised over $220 million.

Rubius has developed the technology to grow, genetically engineer and mature long-circulating Red-Cell Therapeutics™ (RCT™) products, which have the potential to provide transformational clinical benefits to a wide range of patients across multiple therapeutic areas. These allogeneic, off-the-shelf products offer the additional advantage of extended stability and storage to allow for rapid, universal access by the medical community. Proceeds from the financing will be used to accelerate the development of the Company’s portfolio of RCTs™ towards clinical proof-of-concept, and to enhance its manufacturing capacity and capabilities.

Rubius Therapeutics, a 2017 “Fierce 15” award winner, is creating RCTs™ as a new class of medicines. Leading applications include programs in cancer, enzyme deficiency diseases and the induction of tolerance to treat autoimmune disease. The company, led by Torben Straight Nissen, Chris Carpenter and Andrew Oh, is based in Cambridge (MA).

The Goodwin team was led by partners Stuart Cable (Picture) and Arthur McGivern and associate Sarah Ashfaq.

Involved fees earner: Stuart Cable – Goodwin Procter; Arthur McGivern – Goodwin Procter; Sarah Ashfaq – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Rubius Therapeutics;


Author: Ambrogio Visconti